BiotechPark with Innovation- and Incubationscenter

Berlin-Buch, with its long tradition of excellent biomedical basic and clinical research as well as clinical expertise, is an ideal environment for life science companies. The campus atmosphere is conducive to scientific exchange, technology transfer and collaborative projects.
With an area of approximately 45,000 m², the BiotechPark Berlin-Buch is one of the largest biotech parks in Germany. Here entrepreneurs and companies find affordable, industry-specific laboratory and office space with state-of-the-art facilities. Start-ups can grow and thrive in the Innovation and Incubation Center, building areas on the Campus allow for future development. The managing company, Campus Berlin-Buch GmbH, supports the companies in all matters and provides comprehensive service.
Currently, 75 companies are located on campus and employ around 850 people. More than fifty of these companies are in the biotech sector, several others offer services for the life science industry. Since 1998 the number of employees of the biotech companies has more than doubled.
The business fields of the companies range from medical technology products, molecular biological diagnostics and treatments, preclinical pharmacological and pharmacogenomic tests, RNA technologies, the search for pharma-relevant target molecules, production and testing of drugs and the analysis and synthesis of biomolecules.
From 2023 the new BerlinBioCube start-up center in BiotechPark Berlin-Buch will offer an additional 8,000 square meters of laboratory and office space and attractive services for start-ups in the fields of biotechnology and medical technology as well as adjacent areas.
„Made in Buch“ stands for high quality and innovation in the life sciences. Selected products can be found here.

News innovation
U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics’ Proprietary Radiopharmaceutical Cancer Therapy
225Ac-satoreotide is a first-in-class Actinium-labelled somatostatin receptor 2 antagonist targeting extensive-stage Small Cell Lung Cancer or Merkel Cell Carcinoma
more ...Eckert & Ziegler Signs Licence Agreement for Actinium-225 with Chinese Joint Venture
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) today signed a licence agreement with Qi Kang Medical, Ltd (QKM), a joint venture between Eckert & Ziegler and the Chinese company DC Pharma, for the cy...
more ...FDA Clears Ariceum Therapeutics’ 225Ac-Satoreotide Phase I/II Clinical Study in Patients with Small Cell Lung Cancer or Merkel Cell Carcinoma
225Ac-SSO110 (satoreotide) is a first in class Actinium-labelled SSTR2 receptor antagonist. Phase I/II SANTANA-225 study on track to enrol patients in Q1 2025
more ...Events Campus
26.02.2025, 10:00
JUGEND FORSCHT – 60. Regional-Wettbewerb „Macht aus Fragen Antworten”
Die Pateneinrichtungen des Campus Berlin-Buch richten erneut den Regionalwettbewerb aus
more ...12.03.2025, 08:30
vocatium Berlin focus 2025
Über Berufe und Bildungswege informieren: Fachmesse für Ausbildung+Studium MINT-Zukunftsberufe, Praktika, Freiwilliges Jahr
more ...14.03.2025, 08:30
Einladung: UniStem Day für Berliner Schüler:innen / Bio-Leistungskurse
Das German Stem Cell Network (GSCN) lädt die an Biologie interessierten Berliner Schülerinnen und Schüler (Biologie-Leistungskurse und Grundkurse) mit ihren Lehrerkräften herzlich zum UniStem Day – zu...
more ...